The effect of long-term treatment with coenzyme Q10 on nucleic acid modifications by oxidation in children with Down syndrome

Neurobiol Aging. 2018 Jul:67:159-161. doi: 10.1016/j.neurobiolaging.2018.03.001. Epub 2018 Mar 15.

Abstract

Elevated levels of oxidative nucleic acid modifications have been proposed to be associated with some of the clinical characteristics of Down syndrome. Oral intake of coenzyme Q10 improves oxidative status and shows a tendency toward protective effect on DNA oxidation in certain age groups of children with Down syndrome. Here, we demonstrate that long-term (i.e., 4 years) treatment with coenzyme Q10 (ubiquinone) at the dosage of 4 mg/kg/d does not affect whole body DNA and RNA oxidation.

Keywords: 8-Oxo-7,8-dihydro-2′-deoxyguanosine; 8-Oxo-7,8-dihydroguanosine; Down syndrome; Oxidative nucleic acid modifications; Oxidative stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Biomarkers / urine
  • Child
  • DNA / metabolism*
  • Deoxyadenosines / urine
  • Down Syndrome / drug therapy*
  • Down Syndrome / etiology*
  • Down Syndrome / metabolism
  • Guanine / analogs & derivatives
  • Guanine / urine
  • Humans
  • Oxidation-Reduction / drug effects*
  • Oxidative Stress / drug effects*
  • RNA / metabolism*
  • Time Factors
  • Ubiquinone / administration & dosage
  • Ubiquinone / analogs & derivatives*
  • Ubiquinone / pharmacology

Substances

  • Biomarkers
  • Deoxyadenosines
  • Ubiquinone
  • 8-hydroxyguanine
  • Guanine
  • 2'-deoxy-7,8-dihydro-8-oxoadenosine
  • RNA
  • DNA
  • coenzyme Q10